Insider Conviction: Why Coastlands Capital is Buying Adial Pharmaceuticals Ahead of a Pivotal Phase 3

Related Articles

Insider Conviction: Why Glenbrook Capital is Betting Big on SenesTech's Turnaround

3 weeks ago

AI's Profit Paradox: Navigating the Next Phase of Tech Investment

6 months ago

Insider Conviction Fuels Wrap Technologies' Strategic Rebound

1 months ago

Is Inovio Pharmaceuticals (INO) a High-Stakes Bet Ahead of its October PDUFA Date

2 months ago

Category

You may also like

Stock News•3 weeks ago

Playing The Biotech Breakout With Insiders

AbCellera Biologics and Alpha Cognition are highlighted for insider buying and revenue growth. ABCL's Phase 2 data for ABCL635 in Q3 and ACOG's Zunveyl sales ramp are key catalysts, with analyst targe...

ABCL

Share

Stock News•1 months ago

Insider Buying: Bonk, Inc. President Mitchell Rudy Executes Fourth Consecutive Open-Market Purchase, Acquiring 10,000 Additional Shares

Bonk, Inc. President Mitchell Rudy bought 10,000 additional shares at ~$1.21 each, marking his fourth consecutive open-market purchase. Recent acquisitions total over 43,000 shares, signaling executiv...

BNKK

Share

Stock News•2 months ago

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals acquired Azora Therapeutics and secured up to $64M in financing, positioning the combined entity to advance an ulcerative colitis pipeline toward a Phase 1 initiation in mid-2027...

ADIL

Share

Stock News•3 months ago

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 49.4% in April

Adial Pharmaceuticals (ADIL) short interest fell by 49.4% to 49,013 shares as of April 15, down from 96,887 shares on March 31. The current short position represents 3.5% of the company's total outsta...

ADIL

Share